Zynerba Pharmaceuticals (NASDAQ: ZYNE)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-14 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.240 | -0.240 | 0.0000 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Zynerba Pharmaceuticals (NASDAQ: ZYNE) through any online brokerage.
Other companies in Zynerba Pharmaceuticals’s space includes: Opiant Pharma (NASDAQ:OPNT), Cocrystal Pharma (NASDAQ:COCP), SCYNEXIS (NASDAQ:SCYX), Ocuphire Pharma (NASDAQ:OCUP) and Lipocine (NASDAQ:LPCN).
The latest price target for Zynerba Pharmaceuticals (NASDAQ: ZYNE) was reported by Canaccord Genuity on Thursday, June 23, 2022. The analyst firm set a price target for 11.00 expecting ZYNE to rise to within 12 months (a possible 809.09% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Zynerba Pharmaceuticals (NASDAQ: ZYNE) is $1.21 last updated August 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Zynerba Pharmaceuticals.
Zynerba Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 14, 2022.
There is no upcoming split for Zynerba Pharmaceuticals.
Zynerba Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.